These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1456195)

  • 21. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
    Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
    Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
    Hanefeld M; Fischer S
    MMW Fortschr Med; 2003 Feb; 145(9):30-4. PubMed ID: 12666526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy.
    Yu HM; Kim SJ; Chun SW; Park KY; Lim DM; Lee JM; Hong JH; Park KS
    Diabetes Res Clin Pract; 2019 Sep; 155():107796. PubMed ID: 31326458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.
    Holman RR
    Metabolism; 2006 May; 55(5 Suppl 1):S2-5. PubMed ID: 16631806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term effects of glipizide at the pancreatic and extra-pancreatic level in non-insulin dependent diabetics].
    Sánchez MS; Ordóñez AJ; Villalba MT; de la Viña S; Nash RE; Serrano M
    Rev Med Chil; 1984 Feb; 112(2):107-14. PubMed ID: 6377432
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of insulin and oral anti-diabetic agents on glucose metabolism, vascular dysfunction and skeletal muscle inflammation in type 2 diabetic subjects.
    Joya-Galeana J; Fernandez M; Cervera A; Reyna S; Ghosh S; Triplitt C; Musi N; DeFronzo RA; Cersosimo E
    Diabetes Metab Res Rev; 2011 May; 27(4):373-82. PubMed ID: 21309063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination sulfonylurea-insulin therapy in the treatment of noninsulin-dependent diabetes mellitus.
    Rosenblatt J
    Conn Med; 1991 Nov; 55(11):634-6. PubMed ID: 1790695
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.
    Kabadi MU; Kabadi UM
    Ann Pharmacother; 2003 Nov; 37(11):1572-6. PubMed ID: 14565810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.
    Ravnik-Oblak M; Mrevlje F
    Diabetes Res Clin Pract; 1995 Oct; 30(1):27-35. PubMed ID: 8745203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis.
    Hirst JA; Farmer AJ; Dyar A; Lung TW; Stevens RJ
    Diabetologia; 2013 May; 56(5):973-84. PubMed ID: 23494446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes.
    Bell DS; Ovalle F
    Diabetes Obes Metab; 2006 Jan; 8(1):110-5. PubMed ID: 16367889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 35. Triple oral anti-diabetic therapy in type 2 diabetes.
    Barnett AH
    Diabet Med; 2003 Jan; 20 Suppl 1():14-6. PubMed ID: 12647835
    [No Abstract]   [Full Text] [Related]  

  • 36. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent.
    Osei K; Falko JM
    Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for the association of sulfonylurea and insulin.
    Del Prato S
    Am J Med; 1991 Jun; 90(6A):77S-82S. PubMed ID: 1872309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.
    Seufert J; Urquhart R
    Diabetes Res Clin Pract; 2008 Mar; 79(3):453-60. PubMed ID: 18160120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanism of action of sulfonylureas at the pancreatic and extra-pancreatic levels in prolonged treatment in noninsulin-dependent diabetic patients].
    Serrano Ríos M; Ordoñez Pérez AJ; Sánchez Arriarán MS; Villalba Díaz MT; Nash Raina RE; de la Viña S
    Rev Clin Esp; 1983 Dec; 171(6):385-90. PubMed ID: 6369443
    [No Abstract]   [Full Text] [Related]  

  • 40. Diabetic control with gliquidone--a short acting sulphonylurea.
    Borthwick LJ; Wilson S
    Eur J Clin Pharmacol; 1984; 26(4):475-9. PubMed ID: 6428917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.